Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supaglutide DDI with Digoxin or Metformin
NCT05694221Phase 1Completed
- Sponsor
- Shanghai Innogen Pharmaceutical Technology Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of efsubaglutide alfa in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd. Primary endpoints: Plasma Cmax of digoxin at 39 Days, Plasma AUC0-last of digoxin at 39 Days and 3 more. Started Mar 2023; status: completed.
02
Drugs
efsubaglutide alfa
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05694221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694221.